Sarcoma: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• KRAS 10
• TP53 1
• PD-1 19
• PD-L1 9
• PI3K 0
• AKT 0
• NTRK 2
• mTOR 0
• STAT3 0
• MAPK 0
• CTNNB1 0
• MDM2 2
• BRAF 3
• MYC 0
• RAS 3
• ERK 0
• JNK 0
• VEGF 3
• ALK 2
• B7-H3 10
• STING 1
• CDK4/6 3
• EGFR 1
• JAK 1
• PARP 4
• YAP 0
• IDH 2
• FGFR 2
• HER2 5
• MEK 2
• CTLA-4 5
• NRAS 0
• GPX4 0
• HIF-1 0
• PTEN 0
• EZH2 0
• PPAR 0
• METTL3 1
• NF1 5
• AMPK 0
• GPC3 5
• PDGFR 3
• ABL1 0
• CD47 0
• COX-2 0
• ROS1 2
• AXL 0
• CDKN2A 0
• CXCR4 0
• IL-15 4
• MMP-9 0
• PRAME 1
• PSMA 0
• RET 0
• BCL-2 0
• BRCA2 1
• CD19 2
• FLT3 0
• FTO 0
• HDAC 0

17 of 17+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NEI · R43

  Novel gene mutation agnostic small molecule to treat retinitis pigmentosa

  Mitochem Therapeutics Inc.· Charleston, United States· US$320,790 awarded in fiscal year 2026· until Aug 2027

• NIH NCI · F31

  Assessing autophagic dependencies in the context of RAS inhibition in pancreatic ductal adenocarcinoma

  Univ of North Carolina Chapel Hill· Chapel Hill, United States· US$37,011 awarded in fiscal year 2026· until Sept 2029

• NIH NIA · R01

  Synapse repair in Alzheimer's disease and related dementias

  Buck Institute for Research on Aging· Novato, United States· US$785,081 awarded in fiscal year 2026· until Jul 2031

• NIH NINDS · R43

  Development of an Anti-Nerve Growth Factor Active Immunotherapy for Difficult-to-Manage Pain

  Twilight Bioscience, Inc.· Topsfield, United States· US$350,188 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · R16

  Mechanisms of lymphoma cell dissemination to the brain

  North Park University· Chicago, United States· US$162,527 awarded in fiscal year 2026· until Aug 2030

• European Commission (Horizon Europe) · HORIZON-RIA

  immunoTHErapies targeting neOgenes in paeDiatric and adOlescent saRcomAs (THEODORA)

  Institut Curie· Paris, France· EU contribution €8,712,800· until Feb 2032· 5 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Primary bone cancer scaffolds as controlled release non-viral gene delivery platforms (PANACEA)

  Royal College of Surgeons in Ireland· Dublin 2, Ireland· EU contribution €2,302,626· until May 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Self-Assembling, Self-Monitoring, Multi-Stimuli-Responsive Implants for the Minimally Invasive Treatment of Critical-Size Defects (Morphogenesis)

  Fundacion Imdea Materiales· Getafe, Spain· EU contribution €194,075· until Mar 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Investigating the role of RNA-binding proteins in telomere replication stress and alternative lengthening of telomeres (RBPandALT)

  The Francis Crick Institute Limited· London, United Kingdom· EU contribution €260,348· until Mar 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  Pioneering antibody-drug conjugates targeting the tumour microenvironment to deliver transformative new therapies in oncology (ONCO-DART)

  Oncomatryx Biopharma Sa· Derio, Spain· EU contribution €2,499,376· until Oct 2027

  The disease is named only in the funder's project summary, not in the title.

10 of 1,624 running projects, newest first. Listed amounts together: US$944.4m + €86.8m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma

  NCT03116529· University of Maryland, Baltimore· Updated 5 Nov 2026

  “Limited Accrual”Registry text, quoted unchanged. Source

• Suspended

  Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC

  NCT07639242· UNC Lineberger Comprehensive Cancer Center· Updated 28 Aug 2026

  “Administrative”Registry text, quoted unchanged. Source

• Terminated

  A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

  NCT04260802· Ocellaris Pharma, Inc.· Updated 12 Jan 2026

  “Business Decision”Registry text, quoted unchanged. Source

• Terminated

  A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

  NCT02936102· Novartis Pharmaceuticals· Updated 14 Nov 2025

  “The early termination was based on a business decision that FAZ053 would no longer be formulated and was not a consequence of any safety concern.”Registry text, quoted unchanged. Source

• Terminated

  Study on TSR-042 in Advanced Clear Cell Sarcoma

  NCT04274023· Italian Sarcoma Group· Updated 1 Feb 2024

  “Difficulty of enrollment”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma

  NCT04458922· National Cancer Institute (NCI)· Source

• A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

  NCT06345729· Merck Sharp & Dohme LLC· Source

• KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

  NCT07252739· Merck Sharp & Dohme LLC· Source

• A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

  NCT06066138· National Cancer Institute (NCI)· Source

• A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

  NCT06008093· AstraZeneca· Source

• Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

  NCT04902443· National Cancer Institute (NCI)· Source

• Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas

  NCT04242238· Memorial Sloan Kettering Cancer Center· Source

• A phase II study to assess the efficacy of the anti-PD-L1 antibody atezolizumab (MPDL3280A) administered with stereotactic ablative radiotherapy (SABR) in patients with metastatic tumours (SABR-PDL1)

  2024-515678-29-00· Institut Gustave Roussy· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 41
• Organoids 10
• Mendelian Randomization Analysis 2
• CRISPR-Cas Systems 11
• Gene Expression Profiling 99
• Sequence Analysis, RNA 21
• Whole Genome Sequencing 4
• Exome Sequencing 14
• Proteomics 31
• Metabolomics 7
• Mass Spectrometry 5
• Flow Cytometry 52
• Immunohistochemistry 186
• Liquid Biopsy 12
• Circulating Tumor DNA 19
• Xenograft Model Antitumor Assays 153
• Positron-Emission Tomography 19
• Magnetic Resonance Imaging 198
• Machine Learning 29
• Deep Learning 16
• Cohort Studies 30
• Genome-Wide Association Study 2

• Preclinical evaluation of 68Ga-labelled Pt(IV)-DFO complexes as PET-imaging agents for osteosarcoma.

  Eur J Med Chem, Sept 2026

• Omitting Bone Marrow Sampling in FDG-Avid Rhabdomyosarcoma With 2-[18F]FDG PET-Negative Marrow: Results From an International Retrospective Study.

  J Clin Oncol, Aug 2026

• PET radiotracers targeting MDM2 protein interaction: From preclinical validation to first-in-human studies.

  Pharmacol Res, Jun 2026

• Evaluation of standardized uptake value (SUV) and apparent diffusion coefficient (ADC) as prognostic imaging parameters for primary Ewing sarcoma in hybrid 18F-FDG-PET/MRI.

  Eur J Radiol, Jun 2026

• Diagnostic value of integrated 18 F-fluorodeoxyglucose PET/MRI in initial staging and recurrence detection of Ewing sarcoma.

  Nucl Med Commun, Jun 2026

• Current Practices and Variations in the Use of FDG-PET and Bone Marrow Biopsy in Ewing Sarcoma Diagnosis: A Survey of Provider Recommendations.

  J Pediatr Hematol Oncol, Jun 2026

• Mucoid impaction presenting as a solitary pulmonary mass mimicking lung malignancy.

  BMJ Case Rep, Jun 2026

• Role of diffusion-weighted MRI in assessing Ewing sarcoma treatment response: Findings from a COG phase III trial.

  Magn Reson Imaging, May 2026

• Mass Dose Effects in FAP-Directed Imaging: Influence of Administered Dose of [68Ga]Ga-LNTH-1363S on Image Quality.

  J Nucl Med, Apr 2026

• Synthesis and evaluation of RG7388-based fluorinated MDM2 inhibitors for developing 18F-labeled probes for PET imaging.

  Eur J Med Chem, Mar 2026

See which targets of this disease your abstract mentions, and go to the people working on them.